(Sharecast News) - RUA Life Sciences reported a sharp improvement in earnings and cash burn for the 18 months ended 30 September on Friday, after doubling revenues and strengthening its contract development and manufacturing business through an acquisition.
The AIM-traded medical device-focused contract development and manufacturing organisation (CDMO) generated revenues of...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE